RE: AGM ? ...............kickinghorse3
K3........"E1 int will be released as soon as the data management is complete. In my experience it could be released on December 27th and stock will either fly or sink. As there is no established primary end point results could be fuzzy unless stellar.".... end quote
K3 I beg to differ in that there ARE primary endpoints for these Clinical Trials.........from ClinicalTrials.gov Identifier: NCT00239187......
Primary Outcomes: To evaluate the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes.
Secondary Outcomes: To evaluate the pharmacokinetic (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes.
Expected Total Enrollment: 20
Study start: June 2005; Study completion: February 2007
Last follow-up: December 2006; Data entry closure: February 2007
K3....It's the same Primary and same Secondary for TypeII.......
I fail to see how you can say there are no established endpoints and the results may be fuzzy if less than stellar using that reasoning......perhaps you could elaborate if I'm not quite understandig what you're trying to say.
......BTW thanks for asking the question